Efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy for malignant pleural effusion: a meta-analysis.
Efficacy
Hyperthermic perfusion chemotherapy
Malignant pleural effusion
Safety
Systematic review
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
06 May 2024
06 May 2024
Historique:
received:
11
08
2023
accepted:
29
03
2024
medline:
7
5
2024
pubmed:
7
5
2024
entrez:
6
5
2024
Statut:
epublish
Résumé
To evaluate the efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy (IPHC) in treating malignant pleural effusion (MPE). PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), VIP Chinese Science and Technology Journal Full-text Database (VP-CSJFD), and Wanfang database were searched by computer from database establishment to January 17, 2024. Relevant randomized controlled articles with IPHC as the observational group and intrapleural perfusion chemotherapy (IPC) as the control group for MPE were included. Then, the methodological quality of the included articles was evaluated and statistically analyzed using Stata 16.0. Sixteen trials with 647 patients receiving IPHC and 661 patients receiving IPC were included. The meta-analysis found that MPE patients in the IPHC group had a more significant objective response rate [RR = 1.31, 95%CI (1.23, 1.38), P < 0.05] and life quality improvement rate [RR = 2.88, 95%CI (1.95, 4.24), P < 0.05] than those in the IPC group. IPHC and IPC for MPE patients had similar incidence rates of asthenia, thrombocytopenia, hepatic impairment, and leukopenia. Compared with IPC, IPHC has a higher objective response rate without significantly increasing adverse reactions. Therefore, IPHC is effective and safe. However, this study is limited by the quality of the literature. Therefore, more high-quality, multi-center, large-sample, rigorously designed randomized controlled clinical studies are still needed for verification and evaluation.
Identifiants
pubmed: 38711077
doi: 10.1186/s13019-024-02751-6
pii: 10.1186/s13019-024-02751-6
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
278Informations de copyright
© 2024. The Author(s).
Références
Thomas R, Francis R, Davies HE, Lee YC. Interventional therapies for malignant pleural effusions: the present and the future. Respirology. 2014;19(6):809–22.
pubmed: 24947955
doi: 10.1111/resp.12328
Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM Stage groupings in the Forthcoming (Eighth) Edition of the TNM classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51.
pubmed: 26762738
doi: 10.1016/j.jtho.2015.09.009
Ferreiro L, Suárez-Antelo J, Álvarez-Dobaño JM, et al. Malignant pleural effusion: diagnosis and management. Can Respir J. 2020;2020:2950751.
pubmed: 33273991
pmcid: 7695997
doi: 10.1155/2020/2950751
Ferreiro L, Suárez-Antelo J, Valdés L. Malignant pleural effusion management. Manejo Del derrame pleural maligno. Arch Bronconeumol (Engl Ed). 2021;57(1):7–8.
pubmed: 32624211
doi: 10.1016/j.arbr.2020.11.007
Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med. 1994;120(1):56–64.
pubmed: 8250457
doi: 10.7326/0003-4819-120-1-199401010-00010
Sakaguchi H, Ishida H, Nitanda H, Yamazaki N, Kaneko K, Kobayashi K. Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion. Lung Cancer. 2017;104:70–4.
pubmed: 28213004
doi: 10.1016/j.lungcan.2016.12.015
Chen WJ, Yuan SF, Yan QY, et al. Intrapleural chemo- and hyperthermotherapies for malignant pleural effusion: a randomized prospective study. Cancer Invest. 2012;30(2):126–30.
pubmed: 22148972
doi: 10.3109/07357907.2011.633292
Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29(5):829–38.
pubmed: 16626967
doi: 10.1016/j.ejcts.2005.12.025
Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer. 2006;54(1):1–9.
pubmed: 16893591
doi: 10.1016/j.lungcan.2006.04.016
Musani AI. Treatment options for malignant pleural effusion. Curr Opin Pulm Med. 2009;15(4):380–7.
pubmed: 19436206
doi: 10.1097/MCP.0b013e32832c6a8a
Wallner KE, DeGregorio MW, Li GC. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res. 1986;46(12 Pt 1):6242–5.
pubmed: 3779644
Hettinga JV, Lemstra W, Konings AW, Kampinga HH. Cisplatin sensitivity and thermochemosensitisation in thermotolerant cDDP-sensitive and -resistant cell lines. Br J Cancer. 1995;71(3):498–504.
pubmed: 7880730
pmcid: 2033632
doi: 10.1038/bjc.1995.100
Cao Y, Zhang Q, Huang Z, et al. Better effect of intrapleural perfusion with hyperthermic chemotherapy by video-assisted thoracoscopic surgery for malignant pleural effusion treatment compared to normothermic chemoperfusion of the pleural cavity. Cancer Med. 2022;11(2):348–57.
pubmed: 34854253
doi: 10.1002/cam4.4450
Liu Y, Wan L, Qu Z, et al. Effect of continuous hyperthermic perfusion chemotherapy on vascular endothelial growth factor and immune function in elderly patients with malignant pleural effusion. Chin J Gerontol. 2016;36(16):3986–7.
Liu Y, Wan L, Gao J, et al. Effect of continuous hyperthermic perfusion chemotherapy on tumor markers in elderly patients with malignant pleural effusion. Chin J Gerontol. 2020;40(2):304–7.
Liang M, Du J, Jiang D, et al. Observation on the therapeutic effect of continuous circulating thoracic hyperthermic perfusion on malignant pleural effusion. Chin J Pulmonary Dis (Electronic Edition). 2016;9(4):415–7.
Zhao C, Wang Y, Li J. Efficacy of kanglaite hyperthermic perfusion in the treatment of malignant pleural effusion. Shanxi Med J. 2015;44(18):2101–2.
Xu X, Zhang W, Wen A, et al. Observation on Kanglaite Hyperthermic Intrapleural infusion in the treatment of advanced malignant pleural effusion. Chin J Clin Oncol Rehab. 2011;18(1):88–90.
Wu C, Li J, Lin K, et al. Clinical efficacy of intrapleural hyperthermic perfusion of Nedaplatin in the treatment of malignant pleural effusion of lung cancer. Chin J Cancer Prev Treat. 2017;9(6):486–8.
Wang C, Wang M. Comparative clinical efficacy of intrapleural perfusion chemotherapy and intrapleural circulatory hyperthermic perfusion chemotherapy in non-small cell lung cancer with concomitant pleural effusion. Henan Med Res. 2020;29(10):1786–7.
Duan F, Qi X, Wan J. Clinical observation on hyperthermic perfusion chemotherapy in the treatment of malignant pleural effusion. J Practical Cancer. 2003;18(6):635–7.
Lu Z, Lu G, Huang J, et al. Clinical observation on hyperthermic perfusion chemotherapy in the treatment of malignant pleural effusion. China Med Herald. 2013;10(12):163–5.
Li Z, Zhang L, Li L. Clinical observation on 30 cases of malignant pleural effusion treated by hyperthermic perfusion chemotherapy. Mod Oncol. 2010;18(8):1565–7.
Guorong Y, Jie M, Sun L. Clinical observation on intrapleural infusion of warm chemotherapy in the treatment of malignant pleural effusion. Occupation Health. 2006;22(15):1217–8.
Liu L, Lu Y, Shao W. Comparison of efficacy of intrapleural infusion chemotherapy and hyperthermic intrapleural circulation chemotherapy in the treatment of pleural effusion in patients with cellular lung cancer. Mod Oncol. 2019;27(11):1895–9.
Cao Y, Zhang Q, Huang Z, Chai Z, Liu J, Wang J, Sun Z, Zhao T, Wang G, Chen G, Han Y, Li Q, Hong X. Better effect of intrapleural perfusion with hyperthermic chemotherapy by video-assisted thoracoscopic surgery for malignant pleural effusion treatment compared to normothermic chemoperfusion of the pleural cavity. Cancer Med. 2022;11(2):348–57.
pubmed: 34854253
doi: 10.1002/cam4.4450
Cao D, Zhang J, Cheng Y. Therapeutic effect of thoracic circulatory hyperthermic perfusion chemotherapy on patients with non-small cell lung cancer combined with pleural effusion. Progress Cancer. 2023;21(1):49–52.
Cao Y, Xu H, Chen Y, et al. Efficacy of thoracoscopic hyperthermic perfusion chemotherapy in the treatment of malignant pleural effusion and its impact on the tumor inflammatory microenvironment. Med Theory Pract. 2022;35(14):2356–8, 2362.
Chen WJ, Yuan SF, Yan QY, Xiong JP, Wang SM, Zheng WE, Zhang W, Sun HY, Chen H, Wu LL. Intrapleural chemo- and hyperthermotherapies for malignant pleural effusion: a randomized prospective study. Cancer Invest. 2012;30(2):126–30.
pubmed: 22148972
doi: 10.3109/07357907.2011.633292
Fukui T, Yokoi K. The role of surgical intervention in lung cancer with carcinomatous pleuritis. J Thorac Dis. 2016;8(Suppl 11):S901–7.
pubmed: 27942413
pmcid: 5124590
doi: 10.21037/jtd.2016.06.36
Zhan Z, Wang X, Yu J, et al. Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites. Future Oncol. 2022;18(10):1259–71.
pubmed: 35114805
doi: 10.2217/fon-2021-0896
Song K, Flores RM. A narrative review of hyperthermic intrathoracic chemotherapy for advanced lung cancer. Ann Transl Med. 2021;9(11):958.
pubmed: 34350273
pmcid: 8263853
doi: 10.21037/atm-20-6514
Kim HC, Kim E, Jeong SW, et al. Magnetic nanoparticleconjugated polymeric micelles for combined hyperthermia and chemotherapy. Nanoscale. 2015;7:16470–80.
pubmed: 26395038
doi: 10.1039/C5NR04130A
Hu R, Ma S, Li H, et al. Effect of magnetic fluid hyperthermia on lung cancer nodules in a murine model. Oncol Lett. 2011;2:1161–4.
pubmed: 22848282
pmcid: 3406544
doi: 10.3892/ol.2011.379
Speit G, Schütz P. Hyperthermia-induced genotoxic effects in human A549 cells. Mutat Res. 2013;747–748:1–5.
pubmed: 23643703
doi: 10.1016/j.mrfmmm.2013.04.008
Zhao P, Jiang H, Su D, et al. Inhibition of cell proliferation by mild hyperthermia at 43˚C with Paris Saponin I in the lung adenocarcinoma cell line PC-9. Mol Med Rep. 2015;11:327–32.
pubmed: 25322761
doi: 10.3892/mmr.2014.2655
Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3:487–97.
pubmed: 12147435
doi: 10.1016/S1470-2045(02)00818-5
Saga T, Sakahara H, Nakamoto Y, et al. Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild hyperthermia. Eur J Cancer. 2001;37:1429–34.
pubmed: 11435076
doi: 10.1016/S0959-8049(01)00138-1
Foo CT, Paterson A, Duckworth A, Herre J. Intrapleural hyaluronidase in viscous malignant mesothelioma pleural effusion. Chest. 2021;160(6):e609–11.
pubmed: 34872672
doi: 10.1016/j.chest.2021.07.031
Murthy V, Katzman D, Sterman DH. Intrapleural immunotherapy: an update on emerging treatment strategies for pleural malignancy. Clin Respir J. 2019;13(5):272–9.
pubmed: 30810270
doi: 10.1111/crj.13010
Chen KH, Yang YS, Chen R et al. Effects of intracavitary administration of elemene combined with nedaplatin on malignant pleural effusion. Bull Cancer. 2021;S0007-4551(21)00360-X. [Published online ahead of print, 2021 Oct 14].
Chen L, Zhu X, Li D, Cai X. Effect of thoracic hyperthermic perfusion with recombinant human endostatin plus nedaplatin in treating pleural effusion in patients with advanced non-small cell lung cancer. J BUON. 2020;25(6):2643–9.
pubmed: 33455108
Ma X, Yao Y, Yuan D, et al. Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One. 2012;7(12):e53449.
pubmed: 23285296
pmcid: 3532165
doi: 10.1371/journal.pone.0053449